Frederique Visscher

Frederique Visscher is an active medical researcher specializing in immunology and transplantation medicine, with recent publications in high-impact journals including Clinical Infectious Diseases and The Lancet Infectious Diseases. As part of the RECOVAC Collaborators group, her work focuses on optimizing vaccine responses in immunocompromised patients, particularly kidney transplant recipients.

Her research expertise centers on vaccine immunogenicity in transplant patients, with particular emphasis on the interplay between immunosuppressive drugs like Mycophenolate Mofetil and Everolimus and vaccine efficacy. Her fingerprint reveals deep specialization in T-cell responses, kidney graft immunology, and viral infection management in organ transplant recipients, with significant contributions to understanding COVID-19 immunity in this vulnerable population.

Analysis of her recent publications shows a clear research trajectory focused on clinical solutions for improving vaccine responses in transplant patients, particularly through strategic modification of immunosuppressive regimens. Her work bridges clinical practice and immunological research, with immediate implications for patient care during infectious disease outbreaks.

Dr. Visscher actively collaborates with leading researchers in nephrology and infectious diseases, contributing to randomized controlled trials that directly impact clinical guidelines for managing transplant recipients during pandemics. Her research demonstrates strong methodological rigor through well-designed clinical trials and sophisticated immune monitoring techniques.